Related Experiment Video
Updated: Jan 22, 2026

Ultrastructural Expansion Microscopy in Three In Vitro Life Cycle Stages of Trypanosoma cruzi
Published on: May 12, 2023
Tamoxifen acts on Trypanosoma cruzi sphingolipid pathway triggering an apoptotic death process
Malena Landoni1, Tamara Piñero1, Luciana L Soprano2
1Universidad de Buenos Aires, FCEN, Departamento de Química Orgánica - CONICET, CIHIDECAR, Intendente Güiraldes 2160, C1428GA, Ciudad Universitaria, Buenos Aires, Argentina.
Abstract:
This study shows the effects of tamoxifen, a known estrogen receptor antagonist used in the treatment of breast cancer, on the sphingolipid pathway of Trypanosoma cruzi, searching for potential chemotherapeutic targets. A dose-dependent epimastigote growth inhibition at increasing concentration of tamoxifen was determined. In blood trypomastigotes, treatment with 10 μM showed 90% lysis, while 86% inhibition of intracellular amastigote development was obtained using 50 μM. Lipid extracts from treated and non-treated metabolically labelled epimastigotes evidenced by thin layer chromatography different levels of sphingolipids and MALDI-TOF mass spectrometry analysis assured the identity of the labelled species. Comparison by HPLC-ESI mass spectrometry of lipids, notably exhibited a dramatic increase in the level of ceramide in tamoxifen-treated parasites and a restrained increase of ceramide-1P and sphingosine, indicating that the drug is acting on the enzymes involved in the final breakdown of ceramide. The ultrastructural analysis of treated parasites revealed characteristic morphology of cells undergoing an apoptotic-like death process. Flow cytometry confirmed cell death by an apoptotic-like machinery indicating that tamoxifen triggers this process by acting on the parasitic sphingolipid pathway.
Insights
Tamoxifen, an anti-cancer drug, disrupts the sphingolipid pathway in Trypanosoma cruzi, leading to parasite death. This study identifies potential new therapeutic targets for treating Chagas disease.
Area of Science:
- Parasitology
- Biochemistry
- Drug Discovery
Background:
- Trypanosoma cruzi causes Chagas disease, a neglected tropical illness.
- The sphingolipid pathway is crucial for parasite survival and a potential drug target.
Purpose of the Study:
- To investigate the effects of tamoxifen on the T. cruzi sphingolipid pathway.
- To explore tamoxifen as a potential chemotherapeutic agent against T. cruzi.
Main Methods:
- Dose-dependent growth inhibition assays for epimastigotes, trypomastigotes, and intracellular amastigotes.
- Metabolic labeling, thin-layer chromatography, MALDI-TOF, and HPLC-ESI mass spectrometry to analyze sphingolipid levels.
- Ultrastructural analysis and flow cytometry to assess cell death mechanisms.
Main Results:
- Tamoxifen inhibited T. cruzi growth in a dose-dependent manner.
- Significant lysis of blood trypomastigotes and inhibition of intracellular amastigotes were observed.
- Tamoxifen treatment dramatically increased ceramide levels and altered ceramide-1P and sphingosine levels, indicating interference with ceramide breakdown.
- Parasites exhibited morphological and molecular characteristics of apoptotic-like cell death.
Conclusions:
- Tamoxifen effectively targets the T. cruzi sphingolipid pathway, inducing an apoptotic-like death process.
- The drug's action on ceramide metabolism suggests a novel mechanism for antiparasitic activity.
- Tamoxifen demonstrates potential as a chemotherapeutic agent for Chagas disease, warranting further investigation.
Related Concept Videos
The Extrinsic Apoptotic Pathway
The Intrinsic Apoptotic Pathway
Antigen Processing Pathways
MHC Class I: Presenting Endogenous...
Forces Acting on Chromosomes
Microtubules and motor proteins exert two types of forces on...
Phagocytosis of Apoptotic Cells
Normal cells contain receptors that prevent them from being recognized...
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...

